SCHEMBL1627615

SCHEMBL1627615

COc1cccc(Br)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
CA2 P00918 2/20 0.48
CA4 P22748 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
MAPK1 P28482 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TUBB1 Q9H4B7 3/20 0.44
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29732515 1.00 SMN1; SMN2 (0.50) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL10842653 0.86 SMN1; SMN2 (0.47) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL364729 0.85 ALDH1A1 (0.46) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL24186496 0.85 SMN1; SMN2 (0.45) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL24186589 0.85 MEN1 (0.38) SMN1; SMN2CA2CA4CA12CA1
Bromomethane SCHEMBL27848237 0.82 SMN1; SMN2 (0.56) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL25434306 0.82 CA1 (0.61) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL27753904 0.82 CA1 (0.61) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL151213 0.82 CA1 (0.61) SMN1; SMN2CA2CA4CA12CA1
SCHEMBL16067896 0.81 NCOA1 (0.47) SMN1; SMN2MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070166609-A1 ADDITIVES FOR NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY USING THE SAME LG CHEM, LTD. (KR) 2007-07-19 US claimed
EP-4131456-B1 ORGANIC LIGHT-EMITTING DEVICE SFC CO LTD (KR) 2026-02-18 EP disclosed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
US-20250048925-A1 NOVEL ORGANIC LIGHT EMITTING DEVICE COMPRISING TWO LIGHT EMITTING LAYERS SFC CO., LTD. (KR) 2025-02-06 US disclosed
WO-2025021193-A1 STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 珂阑(上海)医药科技有限公司 2025-01-30 WO disclosed
WO-2025020191-A1 STEROID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 珂阑(上海)医药科技有限公司 2025-01-30 WO disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
EP-4456703-A1 NOVEL ORGANIC LIGHT EMITTING DEVICE COMPRISING TWO LIGHT EMITTING LAYERS SFC Co., Ltd. (KR) 2024-10-30 EP disclosed
US-12114660-B2 Picolinamide compounds with fungicidal activity CORTEVA AGRISCIENCE LLC (US) 2024-10-15 US disclosed
CN-118414908-A Novel organic light emitting element comprising two light emitting layers SFC株式会社 2024-07-30 CN disclosed
US-4990657-A From an aromatic halide without a phase transfer agent RHONE-POULENC CHIMIE (FR) 1991-02-05 US disclosed
EP-0255794-B1 PROCESS FOR PREPARING AN AROMATIC ACID RHONE-POULENC CHIMIE (FR) 1990-11-07 EP disclosed
US-4918173-A ANTITUMOR AGENTS; CHEMICAL INTERMEDIATES LABORATORIES HOECHST S.A. (FR) 1990-04-17 US disclosed
EP-0255794-A1 Process for preparing an aromatic acid RHONE-POULENC CHIMIE (FR) 1988-02-10 EP disclosed
EP-0207424-A2 Anthracyclins LABORATOIRES HOECHST S.A. (FR) 1987-01-07 EP disclosed
US-4495353-A ETHERIFICATION OF A HALOAROMTIC COMPOUND STERLING DRUG INC. (US) 1985-01-22 US disclosed
EP-0057321-B1 PROCESSES FOR SUBSTITUTION OF AROMATIC ORGANIC COMPOUNDS STERWIN AG. (CH) 1984-03-21 EP disclosed
US-4422955-A REPLACING HALOGEN ATOM ATTACHED TO RING WITH ALKOXY-TYPE SUBSTITUENT USING AS CATALYST A FORMIC ACID ESTER AND A CUPROUS SALT STERLING DRUG INC. (US) 1983-12-27 US disclosed
US-4415577-A ANTIARRHYTHMIA AGENTS KALI-CHEMIE PHARMA GMBH (DE) 1983-11-15 US disclosed
EP-0057321-A1 Processes for substitution of aromatic organic compounds STERWIN AG. (CH) 1982-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP SMN1; SMN2 3657/4885CA2 4029/4885CA4 4053/4885
US-12114660-B2 Picolinamide compounds with fungicidal activity PFAS, CASP2, CYP1A2 SMN1; SMN2 2463/4885CA2 247/4885CA4 1687/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 SMN1; SMN2 4155/4885CA2 3956/4885CA4 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.